[go: up one dir, main page]

NO980299L - Cytokine production inhibitors, their preparations and their use in medicine, as well as methods for their identification - Google Patents

Cytokine production inhibitors, their preparations and their use in medicine, as well as methods for their identification

Info

Publication number
NO980299L
NO980299L NO980299A NO980299A NO980299L NO 980299 L NO980299 L NO 980299L NO 980299 A NO980299 A NO 980299A NO 980299 A NO980299 A NO 980299A NO 980299 L NO980299 L NO 980299L
Authority
NO
Norway
Prior art keywords
compounds
preparations
medicine
identification
methods
Prior art date
Application number
NO980299A
Other languages
Norwegian (no)
Other versions
NO980299D0 (en
Inventor
Paul Thornalley
Original Assignee
Wivenhoe Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wivenhoe Technology Ltd filed Critical Wivenhoe Technology Ltd
Publication of NO980299D0 publication Critical patent/NO980299D0/en
Publication of NO980299L publication Critical patent/NO980299L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Forbindelser eller ligander som inhiberer bindingen av a-oksoaldehyd- modifiserte argininrester omfatter de med formel (I) hvor R: er en aryl- eller alkylgruppe, R2 er et hydrogenatom og R3 og Rt er uavhengig av hverandre valgt fra et hydrogenatom og aryl- og alkylgrupper, inkludert salter, estere eller hydrati- serte former derav. Slike forbindelser kan formuleres sammen med en far- masøytisk bærer for dem og anvendes til å behandle eller forhindre kroniske, kliniske komplikasjoner forbundet med diabetes mellitus, makrovaskulær sykdom og amyloidose forbundet med Alzheimers sykdom og kronisk nyredialyse. Det er også beskrevet visse a-oksoaldehyd- modifiserte argininrester, sammen med deres anvendelse i en fremgangsmåte for screening av testforbindelser med hen- syn på terapeutisk aktivitet.Compounds or ligands which inhibit the binding of α-oxaldehyde-modified arginine residues include those of formula (I) wherein R 1 is an aryl or alkyl group, R 2 is a hydrogen atom and R 3 and R t are independently selected from a hydrogen atom and alkyl groups, including salts, esters or hydrated forms thereof. Such compounds may be formulated with a pharmaceutical carrier for them and used to treat or prevent chronic, clinical complications associated with diabetes mellitus, macrovascular disease and amyloidosis associated with Alzheimer's disease and chronic renal dialysis. Certain α-oxaldehyde modified arginine residues have also been disclosed, along with their use in a method for screening test compounds for therapeutic activity.

NO980299A 1996-05-25 1998-01-23 Cytokine production inhibitors, their preparations and their use in medicine, as well as methods for their identification NO980299L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9611046.5A GB9611046D0 (en) 1996-05-25 1996-05-25 Pharmacological compounds
PCT/GB1997/001415 WO1997045417A1 (en) 1996-05-25 1997-05-23 Cytokine production inhibitors, formulations thereof and their use in medicine, and methods for their identification

Publications (2)

Publication Number Publication Date
NO980299D0 NO980299D0 (en) 1998-01-23
NO980299L true NO980299L (en) 1998-03-24

Family

ID=10794362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980299A NO980299L (en) 1996-05-25 1998-01-23 Cytokine production inhibitors, their preparations and their use in medicine, as well as methods for their identification

Country Status (10)

Country Link
EP (1) EP0859762A1 (en)
JP (1) JPH11510521A (en)
AU (1) AU2910397A (en)
BR (1) BR9702238A (en)
CA (1) CA2227811A1 (en)
GB (1) GB9611046D0 (en)
HU (1) HUP9902796A3 (en)
IL (1) IL123033A0 (en)
NO (1) NO980299L (en)
WO (1) WO1997045417A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CN1997646A (en) 2004-06-16 2007-07-11 惠氏公司 Diphenylimidazopyrimidinamines and diphenylimidazoimidazolamides as β-secretase inhibitors
CN1968945A (en) 2004-06-16 2007-05-23 惠氏公司 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
CN101103034A (en) 2005-01-14 2008-01-09 惠氏公司 Amino-imidazolones that inhibit β-secretase
KR20070107062A (en) 2005-02-01 2007-11-06 와이어쓰 amino-pyridine as inhibitor of β-secretase
JP2008530103A (en) 2005-02-14 2008-08-07 ワイス Azolylacylguanidines as beta-secretase inhibitors
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
KR20080050430A (en) 2005-09-26 2008-06-05 와이어쓰 Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as beta-secretase (CAC) inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7700606B2 (en) 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
JP2010512389A (en) 2006-12-12 2010-04-22 シェーリング コーポレイション Aspartyl protease inhibitor
CL2008000791A1 (en) 2007-03-23 2008-05-30 Wyeth Corp COMPOUNDS DERIVED FROM 2-AMINO-5- (4-DIFLUOROMETOXI-FENIL) -5-FENIL-IMIDAZOLIDIN-4-ONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH EXCESSIVE BACE ACTIVITY, SUCH AS ILLNESS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005205A (en) * 1974-04-24 1977-01-25 Smith Kline & French Laboratories Limited Compositions and methods for inhibiting H2 histamine receptors
GR79384B (en) * 1982-08-20 1984-10-22 Hoechst Uk Ltd
PT77842B (en) * 1982-12-21 1986-05-05 Pfizer Process for preparing dihydropyridines
GB8311443D0 (en) * 1983-04-27 1983-06-02 Smith Kline French Lab Chemical compounds
CA1252788A (en) * 1985-03-12 1989-04-18 William J. Coates Pyridazinone derivatives
FI902321A7 (en) * 1989-05-19 1990-11-20 Eisai Co Ltd Butenoic acid derivatives
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives

Also Published As

Publication number Publication date
BR9702238A (en) 1999-07-27
JPH11510521A (en) 1999-09-14
HUP9902796A2 (en) 2000-04-28
WO1997045417A1 (en) 1997-12-04
NO980299D0 (en) 1998-01-23
EP0859762A1 (en) 1998-08-26
CA2227811A1 (en) 1997-12-04
GB9611046D0 (en) 1996-07-31
HUP9902796A3 (en) 2000-07-28
IL123033A0 (en) 1998-09-24
MX9800670A (en) 1998-09-30
AU2910397A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
NO980299L (en) Cytokine production inhibitors, their preparations and their use in medicine, as well as methods for their identification
CA2597273C (en) Proteasome inhibitors and methods of using the same
ATE193827T1 (en) USE OF 1-2-4-BENZOTRIAZINE OXIDES IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF TUMORS
ATE244220T1 (en) NEW HETEROCYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL USE
DE3687501D1 (en) USE OF GAMMA LINOLIC ACID AND RELATED COMPOUNDS FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING COMPLICATIONS IN DIABETES MELLITUS.
NO973635L (en) Method of inhibiting cell-cell adhesion
MY119350A (en) Propiophenone derivatives and process for preparing the same
NZ530782A (en) Aminoisoxazole derivatives active as kinase inhibitors
ATE295346T1 (en) N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR INHIBITING BETA-AMYLOID RELEASE AND/OR SYNTHESIS THEREOF USING THESE COMPOUNDS
ATE60579T1 (en) PYRROLIDINAMIDE DERIVATIVES WITH ANTIPROPYLENE ENDOPEPTIDASE ACTIVITY, COMPOSITIONS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM.
DK11391A (en) ALKOXY-4 (1H) -PYRIDON DERIVATIVES AND PHARMACOLOGICAL ACCEPTABLE SALTS THEREOF, THEIR PREPARATION AND USE
ATE189601T1 (en) USE OF RALOXIFENE AND ITS ANALOGUES FOR PRODUCING A MEDICATION FOR THE TREATMENT OF VIRAL DISEASES
DE69332353D1 (en) USE OF INHIBITORS OF THE SYNTHESIS OF FATTY ACIDS FOR THE TREATMENT OF CANCER
DE4111394A1 (en) AMIDINOPHENYLALANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AND MEANS THEREOF
NO955326L (en) Isoquinoline derivatives, process for their preparation and therapeutic use
NO944933L (en) Procedure for inhibiting disease states of the breast
JPH0363294A (en) Novel compound, its preparation and pharmaceutical composition containing same
DK549388D0 (en) 17-ANDROSTANCAN CARBOXYLIC ACID ESTERS, PROCEDURES FOR PREPARING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
ATE18549T1 (en) 1-CARBOXYALKANOYLINDOLINE-2-CARBONIC ACID ESTER, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR THERAPEUTIC USE.
DE69432124D1 (en) USE OF AN INOSITOL TRIPHOSPHATE ESTER FOR THE PRODUCTION OF A MEDICINE
EP0532553B1 (en) Use of compounds for the treatment of age-related memory impairment and other cognitive disorders
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
NO950665L (en) New polyiodized compounds, methods of their preparation and contrast agents containing them
DE69818051D1 (en) N-BENZENESULFONYL-L-PROLIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR THERAPEUTIC USE
Lum et al. Thrombin receptor activation peptide induces pulmonary vasoconstriction